165 related articles for article (PubMed ID: 32466195)
1. A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1.
Ellinger B; Pohlmann D; Woens J; Jäkel FM; Reinshagen J; Stocking C; Prassolov VS; Fehse B; Riecken K
Viruses; 2020 May; 12(5):. PubMed ID: 32466195
[TBL] [Abstract][Full Text] [Related]
2. A novel high-throughput cellular screening assay for the discovery of HIV-1 integrase inhibitors.
Van Loock M; Meersseman G; Van Acker K; Van Den Eynde C; Jochmans D; Van Schoubroeck B; Dams G; Heyndrickx L; Clayton RF
J Virol Methods; 2012 Feb; 179(2):396-401. PubMed ID: 22172974
[TBL] [Abstract][Full Text] [Related]
3. [Universal modular system for in vitro screening of potential inhibitors of HIV-1 replication].
Prokof'eva MM; Orlova NN; Gornostaeva AS; Shul'gin AA; Nikitenko NA; Senchenko VN; Lebedev TD; Spirin PV; Riechen K; Fehse B; Stocking C; Prasolov VS
Mol Biol (Mosk); 2014; 48(2):344-8. PubMed ID: 25850304
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay.
Garcia JM; Gao A; He PL; Choi J; Tang W; Bruzzone R; Schwartz O; Naya H; Nan FJ; Li J; Altmeyer R; Zuo JP
Antiviral Res; 2009 Mar; 81(3):239-47. PubMed ID: 19118579
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening of viral entry inhibitors using pseudotyped virus.
Basu A; Mills DM; Bowlin TL
Curr Protoc Pharmacol; 2010 Dec; Chapter 13():Unit 13B.3. PubMed ID: 21935898
[TBL] [Abstract][Full Text] [Related]
6. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research.
Schambach A; Galla M; Modlich U; Will E; Chandra S; Reeves L; Colbert M; Williams DA; von Kalle C; Baum C
Exp Hematol; 2006 May; 34(5):588-92. PubMed ID: 16647564
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening identifies compounds that enhance lentiviral transduction.
Johnston JM; Denning G; Moot R; Whitehead D; Shields J; Le Doux JM; Doering CB; Spencer HT
Gene Ther; 2014 Dec; 21(12):1008-20. PubMed ID: 25231175
[TBL] [Abstract][Full Text] [Related]
9. Introducing a cleavable signal peptide enhances the packaging efficiency of lentiviral vectors pseudotyped with Japanese encephalitis virus envelope proteins.
Liu H; Wu R; Yuan L; Tian G; Huang X; Wen Y; Ma X; Huang Y; Yan Q; Zhao Q; Cao S; Wen X
Virus Res; 2017 Feb; 229():9-16. PubMed ID: 27993624
[TBL] [Abstract][Full Text] [Related]
10. Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.
Mendenhall A; Lesnik J; Mukherjee C; Antes T; Sengupta R
J Vis Exp; 2012 Apr; (62):e3171. PubMed ID: 22508377
[TBL] [Abstract][Full Text] [Related]
11. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.
Bell AJ; Fegen D; Ward M; Bank A
Exp Biol Med (Maywood); 2010 Oct; 235(10):1269-76. PubMed ID: 20876083
[TBL] [Abstract][Full Text] [Related]
12. Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.
Jegede O; Khodyakova A; Chernov M; Weber J; Menéndez-Arias L; Gudkov A; Quiñones-Mateu ME
Antiviral Res; 2011 Aug; 91(2):94-8. PubMed ID: 21600931
[TBL] [Abstract][Full Text] [Related]
13. A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid.
Zhang DW; Luo RH; Xu L; Yang LM; Xu XS; Bedwell GJ; Engelman AN; Zheng YT; Chang S
Antiviral Res; 2019 Sep; 169():104544. PubMed ID: 31254557
[TBL] [Abstract][Full Text] [Related]
14. Reporter gene expression from LTR-circles as tool to identify HIV-1 integrase inhibitors.
Van Loock M; Hombrouck A; Jacobs T; Winters B; Meersseman G; Van Acker K; Clayton RF; Malcolm BA
J Virol Methods; 2013 Feb; 187(2):238-47. PubMed ID: 23178583
[TBL] [Abstract][Full Text] [Related]
15. Stability of Retroviral Vectors Against Ultracentrifugation Is Determined by the Viral Internal Core and Envelope Proteins Used for Pseudotyping.
Kim SH; Lim KI
Mol Cells; 2017 May; 40(5):339-345. PubMed ID: 28535668
[TBL] [Abstract][Full Text] [Related]
16. FAITH - Fast Assembly Inhibitor Test for HIV.
Hadravová R; Rumlová M; Ruml T
Virology; 2015 Dec; 486():78-87. PubMed ID: 26410239
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay.
Michelini Z; Galluzzo CM; Negri DR; Leone P; Amici R; Bona R; Summa V; Di Santo R; Costi R; Pommier Y; Marchand C; Palmisano L; Vella S; Cara A
J Virol Methods; 2010 Sep; 168(1-2):272-6. PubMed ID: 20558207
[TBL] [Abstract][Full Text] [Related]
18. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
[TBL] [Abstract][Full Text] [Related]
19. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
20. An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitors.
Van Loock M; Van den Eynde C; Hansen J; Geluykens P; Ivens T; Sauviller S; Bunkens L; Van Acker K; Nijs E; Dams G
Assay Drug Dev Technol; 2013 Oct; 11(8):489-500. PubMed ID: 24144343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
